Cardiopulmonary exercise testing as a prognosis-assessing tool in heart failure with preserved ejection fraction.

IF 3.2 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS ESC Heart Failure Pub Date : 2025-01-16 DOI:10.1002/ehf2.15219
C Rozados da Conceicao, A Krannich, V Zach, R Pinto, A Deichl, A Feuerstein, L Schleussner, F Edelmann
{"title":"Cardiopulmonary exercise testing as a prognosis-assessing tool in heart failure with preserved ejection fraction.","authors":"C Rozados da Conceicao, A Krannich, V Zach, R Pinto, A Deichl, A Feuerstein, L Schleussner, F Edelmann","doi":"10.1002/ehf2.15219","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Patients with heart failure with preserved ejection fraction represent half of the heart failure patients nowadays, an at least steady trend due to the aging of the population. We investigated whether the parameters obtained from cardiopulmonary exercise testing (CPET) correlated with the prognosis of these patients. This prospective observational cohort study assesses the relationship between the CPET parameters peakVO<sub>2</sub> and VE/VCO<sub>2</sub> slope and the number of heart failure hospitalizations or cardiovascular death of these patients.</p><p><strong>Methods and results: </strong>From August 2016 until May 2019, 99 patients from our outpatient unit with newly diagnosed heart failure with preserved ejection fraction underwent CPET. Median follow-up was 30 months [interquartile range, 24-38.5]. We selected peakVO<sub>2</sub> < 14 mL/min/kg and a VE/VCO<sub>2</sub> slope > 34 as threshold values for our primary clinically relevant endpoint, a composite of hospitalization for heart failure or cardiovascular death. Mean age was 75.07 ± 7.31 years, 49% were women, 75% were at NYHA class II and median NTproBNP was 511 pg/mL. Mean peakVO<sub>2</sub> was 15.09 ± 4.75, and mean VE/VCO<sub>2</sub> was 36.05 ± 6.60. During follow-up, there were 207 all-cause hospitalizations, 126 cardiovascular hospitalizations, 58 heart failure hospitalizations and 4 deaths. Over a median follow-up of 30 months, the primary clinically relevant endpoint occurred in 5 of 40 patients (12.5%) with a VE/VCO<sub>2</sub> slope ≤ 34 and in 19 of 59 patients (32.2%) with a VE/VCO<sub>2</sub> slope > 34 [hazard ratio, 2.69; 95% confidence interval (CI), 1.00-7.21; P = 0.04]. On multivariate analysis, VE/VCO<sub>2</sub> slope was independently associated with heart failure hospitalization or cardiovascular death as a terminal event.</p><p><strong>Conclusions: </strong>In patients with heart failure with preserved ejection fraction, a VE/VCO<sub>2</sub> slope > 34 predicts heart failure hospitalizations and cardiovascular death.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ehf2.15219","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Patients with heart failure with preserved ejection fraction represent half of the heart failure patients nowadays, an at least steady trend due to the aging of the population. We investigated whether the parameters obtained from cardiopulmonary exercise testing (CPET) correlated with the prognosis of these patients. This prospective observational cohort study assesses the relationship between the CPET parameters peakVO2 and VE/VCO2 slope and the number of heart failure hospitalizations or cardiovascular death of these patients.

Methods and results: From August 2016 until May 2019, 99 patients from our outpatient unit with newly diagnosed heart failure with preserved ejection fraction underwent CPET. Median follow-up was 30 months [interquartile range, 24-38.5]. We selected peakVO2 < 14 mL/min/kg and a VE/VCO2 slope > 34 as threshold values for our primary clinically relevant endpoint, a composite of hospitalization for heart failure or cardiovascular death. Mean age was 75.07 ± 7.31 years, 49% were women, 75% were at NYHA class II and median NTproBNP was 511 pg/mL. Mean peakVO2 was 15.09 ± 4.75, and mean VE/VCO2 was 36.05 ± 6.60. During follow-up, there were 207 all-cause hospitalizations, 126 cardiovascular hospitalizations, 58 heart failure hospitalizations and 4 deaths. Over a median follow-up of 30 months, the primary clinically relevant endpoint occurred in 5 of 40 patients (12.5%) with a VE/VCO2 slope ≤ 34 and in 19 of 59 patients (32.2%) with a VE/VCO2 slope > 34 [hazard ratio, 2.69; 95% confidence interval (CI), 1.00-7.21; P = 0.04]. On multivariate analysis, VE/VCO2 slope was independently associated with heart failure hospitalization or cardiovascular death as a terminal event.

Conclusions: In patients with heart failure with preserved ejection fraction, a VE/VCO2 slope > 34 predicts heart failure hospitalizations and cardiovascular death.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心肺运动试验作为保留射血分数的心力衰竭的预后评估工具。
目的:保留射血分数的心力衰竭患者占目前心力衰竭患者的一半,由于人口老龄化,这至少是一个稳定的趋势。我们研究了心肺运动试验(CPET)获得的参数是否与这些患者的预后相关。这项前瞻性观察队列研究评估了CPET参数峰值vo2和VE/VCO2斜率与这些患者心力衰竭住院或心血管死亡人数之间的关系。方法和结果:2016年8月至2019年5月,我们门诊部门99例新诊断为心力衰竭并保留射血分数的患者接受了CPET检查。中位随访时间为30个月[四分位数间距24-38.5]。我们选择峰值vo22斜率bbbb34作为主要临床相关终点的阈值,该终点是因心力衰竭或心血管死亡住院的综合指标。平均年龄为75.07±7.31岁,49%为女性,75%为NYHA II级,中位NTproBNP为511 pg/mL。平均峰值vo2为15.09±4.75,平均VE/VCO2为36.05±6.60。随访期间,有207例全因住院,126例心血管住院,58例心力衰竭住院,4例死亡。在中位随访30个月期间,40例VE/VCO2斜率≤34的患者中有5例(12.5%)出现了主要临床相关终点,59例VE/VCO2斜率为bbb34的患者中有19例(32.2%)出现了主要临床相关终点[风险比,2.69;95%置信区间(CI), 1.00-7.21;p = 0.04]。在多变量分析中,VE/VCO2斜率与心衰住院或心血管死亡作为终末事件独立相关。结论:在保留射血分数的心力衰竭患者中,VE/VCO2斜率bbbb34预测心力衰竭住院和心血管死亡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ESC Heart Failure
ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine
CiteScore
7.00
自引率
7.90%
发文量
461
审稿时长
12 weeks
期刊介绍: ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
期刊最新文献
Growth differentiation factor-15 and N-terminal pro-BNP in acute heart failure with preserved ejection fraction. Validation of a biomarker-based mortality score for cardiogenic shock patients: Comparison with a clinical risk score. Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure. Real-world comparative effectiveness of sacubitril/valsartan versus RAS inhibition alone in patients with de novo heart failure. Health-related quality of life across heart failure categories: associations with clinical characteristics and outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1